Nivolumab-IRDye800 (Nivo800)

nivolumab-IRDye800 conjugate · Academic research sponsor (Eben Rosenthal)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Nivolumab-IRDye800 (Nivo800), covering 2026-02-27 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: Window Trial of Fluorescently Labeled Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG) [EARLY_Phase 1]